| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective
|
Fosså, S.D.
|
|
|
34 |
12 |
p. 1165-1174
|
article
|
| 2 |
Annals of Oncology 2018-2023
|
Andre, F.
|
|
|
34 |
12 |
p. 1069-1070
|
article
|
| 3 |
Changing cancer representations toward comprehensive portraits to empower patients in their care journey
|
Franzoi, M.A.
|
|
|
34 |
12 |
p. 1082-1087
|
article
|
| 4 |
Circulating tumour DNA for detection of minimal residual disease in head and neck squamous cell carcinoma: A new hope
|
Jacky Lam, W.K.
|
|
|
34 |
12 |
p. 1080-1081
|
article
|
| 5 |
Diversity in clinical trials in Europe and the USA: a review of a pharmaceutical company’s data collection, reporting, and interpretation of race and ethnicity
|
Candelario, N.M.
|
|
|
34 |
12 |
p. 1194-1197
|
article
|
| 6 |
Editorial Board
|
|
|
|
34 |
12 |
p. iii
|
article
|
| 7 |
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
|
Castelo-Branco, L.
|
|
|
34 |
12 |
p. 1097-1112
|
article
|
| 8 |
Favorable long-term Health Related Quality of Life in cured survivors of testicular cancer management. So, what now?
|
D’Souza, A.
|
|
|
34 |
12 |
p. 1077-1079
|
article
|
| 9 |
High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer
|
Bessa, X.
|
|
|
34 |
12 |
p. 1187-1193
|
article
|
| 10 |
Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma
|
McNeish, I.A.
|
|
|
34 |
12 |
p. 1074-1076
|
article
|
| 11 |
Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
|
Goetz, M.P.
|
|
|
34 |
12 |
p. 1141-1151
|
article
|
| 12 |
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
|
Pujade-Lauraine, E.
|
|
|
34 |
12 |
p. 1152-1164
|
article
|
| 13 |
Moving toward precision oncology centers V2.0
|
Dogan, S.
|
|
|
34 |
12 |
p. 1088-1089
|
article
|
| 14 |
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
|
Damodaran, S.
|
|
|
34 |
12 |
p. 1131-1140
|
article
|
| 15 |
Retraction notice to “CN5 - Examination of mobile applications on breast cancer”
|
Aydin, A.
|
|
|
34 |
12 |
p. 1201
|
article
|
| 16 |
Retraction notice to “CN104 - How should the symptoms be managed after breast cancer surgery? An example of mobile app”
|
Aydin, A.
|
|
|
34 |
12 |
p. 1203
|
article
|
| 17 |
Retraction notice to “CN17 - Using mobile-based health care applications outcomes: Mini systematic review”
|
Aydin, A.
|
|
|
34 |
12 |
p. 1202
|
article
|
| 18 |
Table of Contents
|
|
|
|
34 |
12 |
p. i-ii
|
article
|
| 19 |
The ELAINE trials and the future of personalized therapy for hormone-receptor positive metastatic breast cancer
|
Wander, Seth A.
|
|
|
34 |
12 |
p. 1071-1073
|
article
|
| 20 |
The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review
|
Fulton-Ward, T.
|
|
|
34 |
12 |
p. 1113-1130
|
article
|
| 21 |
Time to treat the climate and nature crisis as one indivisible global health emergency ☆
|
Abbasi, K.
|
|
|
34 |
12 |
p. 1094-1096
|
article
|
| 22 |
Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck
|
Honoré, N.
|
|
|
34 |
12 |
p. 1175-1186
|
article
|
| 23 |
VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
|
Oaknin, A.
|
|
|
34 |
12 |
p. 1198-1200
|
article
|
| 24 |
WGS/WES-RNAseq compared to targeted NGS in oncology: is there something to unlock?
|
Aldea, M.
|
|
|
34 |
12 |
p. 1090-1093
|
article
|
Journal description